Investigating how integrins affect prostate cancer progression
Integrin-mediated mechanisms of prostate cancer progression
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-10524161
This study is looking at how a specific protein called αvβ6 affects the growth of prostate cancer, especially when it stops responding to usual treatments, to find new ways to help patients feel better and improve their care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10524161 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific integrin, αvβ6, in the progression of prostate cancer, particularly in cases that become resistant to standard treatments like chemical castration. The study examines how this integrin influences cancer cell behavior and the surrounding microenvironment, potentially leading to more effective treatment strategies. By analyzing the interactions between cancer cells and their environment, the research aims to identify new therapeutic targets that could improve patient outcomes. The methodology includes in vitro experiments and in vivo studies to assess the effects of integrin inhibition on cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer, particularly those who have developed resistance to chemical castration treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone chemical castration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer that is resistant to current therapies.
How similar studies have performed: Other research has shown promising results in targeting integrins for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LANGUINO, LUCIA R. — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: LANGUINO, LUCIA R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer